Although the molecular defect causing Duchenne/Becker muscular dystrophy (DMD/BMD)
was identified nearly 20 years ago, the development of effective therapeutic strategies has …

Regenerative capacity of skeletal muscles resides in satellite cells, a self-renewing
population of muscle cells. Several studies are investigating epigenetic mechanisms that …

PURPOSE: We explored the use of autologous muscle derived cells as a method of treating
stress urinary incontinence. We determined whether urethral muscle derived cell injection is …

Derivation of functional skeletal muscle stem cells from pluripotent cells without genetic
modification has proven elusive. Here we show that teratomas formed in adult skeletal …

The delivery of genes to skeletal muscle by myoblast implantation, DNA injection, or viral
transduction has therapeutic applications for human neuromuscular and systemic disorders …

Duchenne muscular dystrophy (DMD) is an X-linked progressive degenerative muscle
disorder caused by the absence of dystrophin. There is no curative therapy, although …

Adenovirus-mediated gene transfer to muscle is a promising technology for gene therapy of
Duchenne muscular dystrophy (DMD). However, currently available recombinant …

Clinical trials of cardiovascular gene therapy, whether using viral (53%) or nonviral (47%)
vectors, have thus far disclosed no evidence indicative of inflammatory or other …

Tissue-engineered skeletal muscle is urgently required to treat a wide array of devastating
congenital and acquired conditions. Selection of the appropriate cell type requires …

Myoblast transplantation has been investigated as a therapy for muscle-related diseases
and as a gene delivery vehicle for therapeutic recombinant proteins. Clinical successes …